ReviewJournal of medicinal chemistry2025
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential.
Review in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery.Medicinal research reviews · 2026Review
- Epigenetic Control of Stress-Induced Depression: Emerging Roles of HDAC3 and HDAC6.International journal of molecular sciences · 2026Review
- Review
- MINERVA: a public XAI-powered platform advancing multi-target discovery in Alzheimer's disease.Journal of cheminformatics · 2026Article
- Design, synthesis, and anticancer activity of phenoxyacetohydrazide derivatives in burkitt lymphoma.Scientific reports · 2026Article
- Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases.MedComm · 2026Review
- Epigenetic activation of PDLIM7 via H3K27 acetylation mitigates neuroinflammation and neurodegeneration in parkinson's disease models.Journal of bioenergetics and biomembranes · 2026Article
- Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors.ACS pharmacology & translational science · 2026Review
- Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy.Cells · 2025Review
- Article
- Catalyst-Free Assembly of δ-Lactam-Based Hydrazide-Hydrazone Compounds from 3-Arylglutaconic Anhydrides and Aldazines.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone deacetylase (HDAC) impairment is strongly related to various cancers as well as neurodegenerative and inflammatory diseases. Considering HDACs' crucial role as drug targets, over the past decade, the development of HDAC inhibitors (HDACi) has gained significant interest in the pharmaceutical field. To date, five HDAC inhibitors have been approved by the FDA, and many are currently in clinical trials. Despite the common use of hydroxamic acid and 2-aminoanilide groups as zinc-binding groups (ZBGs) in HDAC inhibitors, concerns about their instability, toxicity, and low bioavailability have led researchers to explore alternative ZBGs. Recently, the hydrazide group has emerged as a promising alternative, offering potentially safer properties and fewer off-target effects. This perspective will discuss recent advancements from a medicinal chemistry point of view related to the hydrazide group's role in HDAC inhibitor development, highlighting their pharmaceutical properties, biological activities, and potential benefits in reducing side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.